Phase 4 Bladder Cancer Trial, Recruiting NCT06781879 Sponsor: Jakob Kristian Jakobsen Condition: Bladder Cancer
Back to Bladder Cancer

Phase 4 Bladder Cancer Trial, Recruiting

NCT06781879
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People whose bladder cancer has come back after a previous low-grade, non-invasive bladder tumour (called Ta low-grade)
  • People whose tumour is smaller than 2 cm across
  • People whose urine test (cytology) did not find any cancer cells — this test is optional
  • People who are 18 years of age or older
  • People who are able to understand the information given to them about the trial, both in writing and verbally
  • People who have given written agreement to take part

Who may not be able to join:

  • People with a known history of a bladder tumour that has grown into the bladder wall (stage T1 or higher)
  • People with a known history of carcinoma in situ (CIS) of the bladder, a type of flat, high-grade bladder cancer
  • People who have previously been treated with MMC (mitomycin C) or BCG, except for a single dose given right after a previous bladder tumour removal procedure
  • People with a known allergy or sensitivity to MMC (mitomycin C)
  • People with a solid tumour that shows signs it may be growing into the bladder wall
  • People whose tumour is located in the bladder neck or urethra (the tube that carries urine out of the body)
  • People where CIS is suspected based on a positive urine test showing high-grade cancer cells combined with suspicious flat areas seen during a bladder examination (cystoscopy)
  • People with a very small bladder (holding less than 100 ml) or who experience urinary incontinence
  • People who have previously had radiation therapy to the pelvic area
  • People currently experiencing an acute bladder infection (cystitis)
  • People who are pregnant or breastfeeding
  • People who are unwilling to use reliable contraception — this applies to men with partners capable of becoming pregnant, and to women who have not yet gone through menopause

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Phone: 0045 78 45 00 00

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Jakob Kristian Jakobsen
Registry
ClinicalTrials.gov
Start date
1 June 2025
Est. completion
1 February 2029

Where this trial is recruiting

🇩🇰 Denmark Iceland 🇳🇴 Norway 🇸🇪 Sweden

Primary endpoints

Two-year Recurrence Free Survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov